Home › Agent Hub › Agent Tools › Part D coverage by drug › Novolin N
Agent Tools
Novolin N is a brand of insulin isophane. What agents check before quoting it: how many 2026 Part D plans cover it, on which tier, with what restrictions and copays, by plan type, carrier and state.
In 2026, 4,245 of 5,496 Medicare Part D and Medicare Advantage drug plans (77.2%) list Novolin N on their formulary, across 299 of 328 formularies. The most common placement is tier 3 (3,870 plans, 91.2% of those covering it). 0 of the covering plans require prior authorization (0%), 0 step therapy and 558 a quantity limit.
1,360 covering plans charge a flat copay for a 30-day supply at a preferred retail pharmacy after the deductible — median $45, 207 of them $0; 2,885 charge coinsurance instead — median 24% of the drug's cost. Covered insulin is capped at $35 for a month's supply.
2025: 3,517 of 5,631 plans covered it (62.5%); 2026: 4,245 of 5,496 (77.2%).
Of 4,368 plans offered in both years, 547 added it to the formulary and 0 dropped it.
Among plans covering it both years, 90 moved it to a higher tier and 10 to a lower one; 0 added prior authorization and 0 removed it.
Medicare Part D paid for 271,714 30-day fills of Novolin N in 2024 for about 43,439 enrollees, at an average total cost of $76.92 per 30-day fill (CMS Part D Prescribers by Geography and Drug, national).
Price Novolin N and the rest of a client's list on every plan in their county.
Estimate Novolin N costs by plan
Free tools for licensed insurance agents. Data from CMS public files; verify with plan documents before advising a client.
Counts are over every Medicare Advantage drug plan and stand-alone Part D plan in the CMS monthly formulary files, excluding employer plans. A plan counts as covering a drug when any strength or form of it is on the plan’s formulary; the tier, prior authorization, step therapy and quantity limit shown are the most favorable version on that formulary. Copays are for a 30-day supply at a preferred retail pharmacy after the deductible. This is a reference for licensed agents, not a plan recommendation; verify with the plan’s formulary before advising a client. Source: CMS Part D formulary files (release 09/16/2026). CMS formulary data.